Biothera Pharmaceuticals Presents Translational Data from Ongoing Clinical Trials Showing Imprime PGG in Combination with Merck’s KEYTRUDA® (pembrolizumab) Drives Innate and Adaptive Immune Responses in Tumors
April 16, 2018 09:00 ET
|
Biothera Pharmaceuticals, Inc.
EAGAN, Minn., April 16, 2018 (GLOBE NEWSWIRE) -- Biothera Pharmaceuticals, Inc. today announced the presentation of new translational data from ongoing phase 2 clinical trials combining Biothera’s...